Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546303 | 1.00 | EGLN1 (0.46) | EGLN1OPRM1OPRD1OPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL3998414 | 0.98 | EGLN1 (0.44) | EGLN1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL29588998 | 0.93 | KCNH2 (0.46) | EGLN1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL539875 | 0.93 | KCNH2 (0.46) | EGLN1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL29589035 | 0.93 | KCNH2 (0.46) | EGLN1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL539874 | 0.93 | KCNH2 (0.46) | EGLN1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL1280052 | 0.93 | KCNH2 (0.46) | EGLN1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL29584516 | 0.93 | KCNH2 (0.46) | EGLN1OPRM1OPRD1OPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL7980093 | 0.92 | KCNH2 (0.45) | EGLN1OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL18435402 | 0.85 | SCN3A (0.54) | OPRM1OPRD1OPRK1KCNH2SCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104161758-A | Applications of tetrahydroisoquinoline-3-carboxylic acid derivatives in preparation of medicines treating dopaminergic nerve diseases | UNIV SOOCHOW | 2014-11-26 | — | — | CN | claimed |
| CN-104161758-A | Applications of tetrahydroisoquinoline-3-carboxylic acid derivatives in preparation of medicines treating dopaminergic nerve diseases | UNIV SOOCHOW | 2014-11-26 | — | — | CN | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | EGLN1 2220/4885OPRM1 1534/4885OPRD1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.